Tag: Valeant Pharmaceuticals

Valeant Pharma and Adobe see bullish pre-market session

VRX – Valeant Pharmaceuticals International, Inc – develops, manufactures and sells pharmaceuticals, OTC products and medical devices. Previously this week, $VRX prices had slumped due to bankruptcy scare. Chances are, it may plunge further, despite a 5% rise pre-market.

VRX- Valeant Pharmaceuticals International, Inc.

Fundamentals Previously closed at 26.69
Day’s high 33.70
Day’s low  29.52
P/E ratio 17.05
EPS 1.74

 

Analysts opinion With the news VRX postponing its annual report filing with SEC due to an ongoing investigation of its finances, and weak forecasts for 2016, the stocks plummeted to new lows in 5 years. The stock has lost atleast 85% of its value since its 1 year high. Today, the CEO, Mike Pearson sent out a memo, assuring the employees, that VRX will not be filing for bankruptcy. It also stated that, it would miss a deadline to file its annual report, which would risk Valeant pharma to fall into defaulting some of its debt unless the annual report was filed within the 60-day cure.
Sentiments The stock rose 5% pre-market, but has mixed sentiments from investors. While some investors are bullish due to CEO’s memo, many are bearish due to the associated risks.
Social Pulse The stock has 100% higher social chatter than usual.

 

Continue Reading…

A couple pharmaceutical companies that may be bearish today

VRX – Valeant Pharmaceuticals International, Inc – a specialty pharmaceutical and medical device company, is famous for its growth by acquisition strategy. It fell 18% on 29th Feb 2016.

VRX – Valeant Pharmaceuticals International, Inc
Fundamentals Previously closed at 65.8
Day’s high 76.95
Day’s low 63.85
P/E ratio 37.79
EPS 1.74

 

Analysts opinion VRX has a PEG ratio of 0.37, P/S ratio of 2.77, and a P/B ratio of 4.36. It has a forward PE of 4.91. Valeant’s CEO Micheal Pearson returned after an indefinate medical leave. VRX postponed the release of its Q4 earnings results and completely withdrew its 2016 guidance. Due to these, the stock price plummetted more than 18% on monday.
Sentiments Post this, many brokers either lowered their price objectives or downgraded the stocks. Deutsche Bank suspended the coverage on the stock. Due to this, the stock may have further bearish sentiments today.
However, Janus Capital Management raised its stakes in VRX during the 3rd quarter last year, which indicates that hedge funds have faith in the business model of the company.
Revenue Prediction The Estimize consensus revenue for VRX is $2.8 billion
Social Pulse The stock has 1% lower social chatter than usual.

 

Continue Reading…